Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies – OncLive
OncLive |
Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies
OncLive Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies. Checkpoint inhibitors are generating more interest, states Lallas. |
